Recombinant FGF21 and FGF21 analogs have emerged as promising therapeutic drug candidates for metabolic disorders, including NAFLD [63,64], and are currently in clinical development for the potential treatment of NASH [32]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.